Hematolo-GIST Training
BehavioralHematologist will participate in a group Hematolo-GIST training provided remotely via the study team.
NCT Number: NCT05940272
The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Memorial Sloan Kettering Cancer Center (All protocol activities), New York, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Providers
Patients
Exclusion criteria
Providers
Patients
Hematologist will participate in a group Hematolo-GIST training provided remotely via the study team.
Participants will meet with Hematolo-GIST trained hematologists. Participants will consent to having their appointment audio-recorded on password-protected devices or MSK approved secure platforms.
Time frame: Up to 1 year
Feasbility is defined as ≥70% of screened eligible hematologists and participants enrolling in the study and ≥80% of hematologists learning the approach
Contact information is provided by the study sponsor or research team.
Kelly McConnell, PhD
CONTACT
Revecca Saracino, PhD
CONTACT
Memorial Sloan Kettering Cancer Center
Other
Evaluation of a Communication Intervention (Hematolo-GIST) for Large B-Cell Lymphoma Providers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07188558
Diffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma Refractory
Gilbert, Arizona, United States
View Trial DetailsNCT06693830
Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
New York, United States
View Trial DetailsNCT03162536
Blood Protein Disorders, Cardiovascular Diseases
Scottsdale, Arizona, United States
View Trial DetailsNCT07502872
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases
Providence, Rhode Island, United States
View Trial Details